Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): A double-blind randomised placebo-controlled phase 3 trial

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1748-1757

  Buyse, Gunnar M ^a   Voit, Thomas ^b   Schara, Ulrike ^c   Straathof, Chiara S M ^d   D'Angelo, M Grazia ^e   Bernert, Günther ^f   Cuisset, Jean Marie ^g   Finkel, Richard S ^h   Goemans, Nathalie ^a   McDonald, Craig M ⁱ   Rummey, Christian ^j   Meier, Thomas ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Istituto di Ricovero e Cura A Carattere Scientifico Eugenio Medea   (Italy)

^f Gottfried von Preyer'sches Kinderspital   (Austria)

^g UNIV LILLE   (France)

^h NEMOURS CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j 4Pharma   (Switzerland)

^k Santhera Pharmaceuticals   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IDEBENONE; PLACEBO; ANTIOXIDANT; UBIQUINONE;

ADOLESCENT; ADULT; AIRWAY PRESSURE; ARTICLE; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HOME MONITORING; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION TEST; MEDICATION COMPLIANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY FUNCTION; RHINOPHARYNGITIS; SLEEP DISORDERED BREATHING; SPIROMETRY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BREATHING MUSCLE; CLINICAL TRIAL; COMPLICATION; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; RESPIRATION DISORDERS; TREATMENT OUTCOME;

ADOLESCENT; ANTIOXIDANTS; CHILD; DOUBLE-BLIND METHOD; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PEAK EXPIRATORY FLOW RATE; RESPIRATION DISORDERS; RESPIRATORY FUNCTION TESTS; RESPIRATORY MUSCLES; TREATMENT OUTCOME; UBIQUINONE;

EID: 84929028797     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60025-3     Document Type: Article

References (40)

1. JR Mendell, M Lloyd-Puryear Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy Muscle Nerve 48 2013 21 26
2. SR Inkley, FC Oldenburg, PJ Vignos Pulmonary function in Duchenne muscular dystrophy related to stage of disease Am J Med 56 1974 297 306
3. RY Rideau, LW Jankowski, J Grellet Respiratory function in the muscular dystrophies Muscle Nerve 4 1981 155 164
4. CM McDonald, RT Abresch, GT Carter et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy Am J Phys Med Rehabil 74 1995 S70 S92
5. S Tangsrud, IL Petersen, KC Lødrup Carlsen, KH Carlsen Lung function in children with Duchenne's muscular dystrophy Resp Med 95 2001 898 903
6. M Kohler, CF Clarenbach, L Böni, T Brack, EW Russi, KE Bloch Quality of life, physical disability, and respiratory impairment in patients with Duchenne muscular dystrophy Am J Respir Crit Care Med 172 2005 1032 1036
7. K Bushby, R Finkel, D Birnkrant for the DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care Lancet Neurol 9 2010 177 189
8. K Bushby, R Finkel, D Birnkrant for the DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, pharmacological and psychosocial management Lancet Neurol 9 2010 77 93
9. EK Henricson, RT Abresch, A Cnaan et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures Muscle Nerve 48 2013 55 67
10. V Ricotti, DA Ridout, E Scott et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy J Neurol Neurosurg Psychiatry 84 2013 698 705
11. RH Haefeli, M Erb, AC Gemperli et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels PLoS One 6 2011 e17963
12. S Jaber, BM Polster Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? J Bioenerg Biomembr 47 2015 111 118
13. GM Buyse, G Van der Mieren, M Erb et al. Long-term placebo-controlled study showing phenotypic correction of dystrophin-deficiency in the mdx mouse by SNT-MC17/idebenone Eur Heart J 30 2009 116 124
14. GM Buyse, N Goemans, M van den Hauwe et al. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial Neuromusc Disord 21 2011 396 405
15. GM Buyse, N Goemans, M van den Hauwe, T Meier Effects of glucocorticoids and idebenone on respiratory function in patients with Duchenne muscular dystrophy Pediatr Pulmonol 48 2013 912 920
16. S Godfrey, PL Kamburoff, JR Nairn Spirometry, lung volumes and airway resistance in normal children aged 5 to 18 years Br J Dis Chest 64 1970 15 24
17. PH Quanjer, J Stocks, G Polgar, M Wise, J Karlberg, G Borsboom Compilation of reference values for lung function measurements in children Eur Respir J Suppl 4 1989 184s 261s
18. JL Hankinson, JR Odencrantz, KB Fedan Spirometric reference values from a sample of the general US population Am J Respir Crit Care Med 159 1999 179 187
19. R Domenech-Clar, JA Lopez-Andreu, L Compte-Torrero et al. Maximal static respiratory pressures in children and adolescents Pediatr Pulmonol 35 2003 126 132
20. LM Gauld, J Kappers, JB Carlin, CF Robertson Prediction of childhood pulmonary function using ulna length Am J Respir Crit Care Med 168 2003 804 809
21. LM Gauld, J Kappers, JB Carlin, CF Robertson Height prediction from ulna length Dev Med Child Neurol 46 2004 475 480
22. LM Gauld, A Boynton Relationship between peak cough flow and spirometry in Duchenne muscular dystrophy Pediatr Pulmonol 39 2005 457 460
23. JR Bach, Y Ishikawa, H Kim Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy Chest 112 1997 1024 1028
24. MF Philipps, RCM Quinlivan, RHT Edwards, PMA Calverley Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy Am J Respir Crit Care Med 164 2001 2191 2194
25. PH Quanjer, MD Lebowitz, I Gregg et al. Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society Eur Respir J Suppl 24 1997 2S 8S
26. A Hahn, JR Bach, A Delaubier, A Renardel-Irani, C Guillou, Y Rideau Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy Arch Phys Med Rehabil 78 1997 1 6
27. AA Suarez, FA Pessolano, SG Monteiro et al. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease Am J Phys Med Rehabil 81 2002 506 511
28. WG Vincken, MG Elleker, MG Cosio Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders Am J Med 83 1987 673 680
29. R Griggs The use of pulmonary function testing as a quantitative measurement for therapeutic trials Muscle Nerve 13 1990 S30 S34
30. Y Khan, JZ Heckmatt Obstructive apnoeas in Duchenne muscular dystrophy Thorax 49 1994 157 161
31. W Vincken, C Guilleminault, L Silvestri, M Cosio, A Grassino Inspiratory muscle activity as a trigger causing the airways to open in obstructive sleep apnea Am Rev Respir Dis 135 1987 372 377
32. OF Pedersen The Peak Flow Working Group: physiological determinants of peak expiratory flow Eur Respir J 10 suppl 24 1997 11s 16s
33. GE Tzelepis, S Zakynthinos, T Vassilakopoulos, S Geroulanos, C Roussos Inspiratory maneuver effects on peak expiratory flow. Role of lung elastic recoil and expiratory pressure Am J Respir Crit Care Med 156 1997 1399 1404
34. V Humbertclaude, D Hamroun, K Bezzou et al. Motor and respiratory heterogeneity in Duchenne patients: implications for clinical trials Eur J Pediatr Neurol 16 2012 149 160
35. PW Noble, C Albera, WZ Bradford for the CAPACITY Study Group Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
36. L Richeldi, RM du Bois, G Raghu et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2014 2071 2082
37. NA Di Prospero, CJ Sumner, SR Penzak, B Ravina, KH Fischbeck, JP Taylor Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia Arch Neurol 64 2007 803 808
38. AC Tzeng, JR Bach Prevention of pulmonary morbidity for patients with neuromuscular disease Chest 118 2000 1390 1396
39. CM McDonald, EK Henricson, RT Abresch et al. The cooperative international neuromuscular research group Duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used Muscle Nerve 48 2013 32 54
40. N Goemans, GM Buyse Current treatment and management of dystrophinopathies Curr Treat Options Neurol 16 2014 287